Trump didn’t exactly come through for pharma
The pharmaceutical industry, despite its outsized lobbying budget and enviable power in Washington, just took a sizable loss when it comes to trade policy.
As STAT’s Nicholas Florko reports, the successor to NAFTA will not include a provision that delays biosimilar competition in Canada and Mexico, amounting to a direct rebuke of the drug lobby. An earlier version of the deal would have promised 10 years of biologics exclusivity. The final agreement makes no mention of it, meaning new biologics will get a five-year monopoly in Mexico and an eight-year one in Canada.
And from pharma’s perspective, that’s bad.
“Honestly, if you looked and said what would Bernie Sanders, what would Elizabeth Warren have negotiated, you probably would not have had a worse [provision] negotiated by them,” one lobbyist said.
Read more.
As STAT’s Nicholas Florko reports, the successor to NAFTA will not include a provision that delays biosimilar competition in Canada and Mexico, amounting to a direct rebuke of the drug lobby. An earlier version of the deal would have promised 10 years of biologics exclusivity. The final agreement makes no mention of it, meaning new biologics will get a five-year monopoly in Mexico and an eight-year one in Canada.
And from pharma’s perspective, that’s bad.
“Honestly, if you looked and said what would Bernie Sanders, what would Elizabeth Warren have negotiated, you probably would not have had a worse [provision] negotiated by them,” one lobbyist said.
Read more.
No hay comentarios:
Publicar un comentario